Perspectives on polycystic ovary syndrome: Is polycystic ovary syndrome research underfunded?

Soumia Brakta, Daria Lizneva, Kateryna Mykhalchenko, Adonis Imam, Walidah Walker, Michael Peter Diamond, Ricardo Azziz

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Context: Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic abnormality with a worldwide prevalence of 4% to 21%, depending on diagnostic criteria. The National Institutes of Health (NIH) is the largest single funding agency in the world; it invests nearly $30.0 billion annually in biomedical research. Evidence Acquisition: Using the NIH Research Portfolio Online Reporting tool, we searched for all grants awarded by the NIH for PCOS and three other disorders with similar degrees of morbidity and similar or lower mortality and prevalence [rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE)]. Evidence Synthesis: We compared funding by the NIH for PCOS, RA, TB, and SLE research for the years 2006 to 2015, inclusive. Conclusion: PCOS, compared with RA, TB, and SLE, was relatively less funded (total mean 10-year funding was $215.12 million vs $454.39 million, $773.77 million, and $609.52 million, respectively). Funding for PCOS was largely provided by one NIH Institute/Center (ICs) vs at least two ICs for SLE and RA; more individual Research Project Grants were awarded for RA, SLE, and TB than for PCOS, whereas PCOS funding was more likely to be through General Clinical Research Centers Program or Specialized Centers Program awards. Our data suggest that PCOS research may be underfunded considering its prevalence, economic burden, metabolic morbidity, and negative impact on quality of life. Greater education of NIH leaders, including those at the National Heart, Lung, and Blood Institute and National Institutes of Diabetes and Digestive and Kidney Diseases; other federal and state agency leads; elected leaders; and the general public by professional societies, the scientific community, and patient advocates regarding this disorder is needed.

Original languageEnglish (US)
Pages (from-to)4421-4427
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume102
Issue number12
DOIs
StatePublished - Jan 1 2017

Fingerprint

Polycystic Ovary Syndrome
National Institutes of Health (U.S.)
Health
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Research
Tuberculosis
Organized Financing
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)
Medical problems
National Heart, Lung, and Blood Institute (U.S.)
Morbidity
Blood
Education
Biomedical Research
Economics
Quality of Life
Mortality

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Perspectives on polycystic ovary syndrome : Is polycystic ovary syndrome research underfunded? / Brakta, Soumia; Lizneva, Daria; Mykhalchenko, Kateryna; Imam, Adonis; Walker, Walidah; Diamond, Michael Peter; Azziz, Ricardo.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 102, No. 12, 01.01.2017, p. 4421-4427.

Research output: Contribution to journalReview article

Brakta, Soumia ; Lizneva, Daria ; Mykhalchenko, Kateryna ; Imam, Adonis ; Walker, Walidah ; Diamond, Michael Peter ; Azziz, Ricardo. / Perspectives on polycystic ovary syndrome : Is polycystic ovary syndrome research underfunded?. In: Journal of Clinical Endocrinology and Metabolism. 2017 ; Vol. 102, No. 12. pp. 4421-4427.
@article{159f6a65bffb4929859e53a1c1908ae0,
title = "Perspectives on polycystic ovary syndrome: Is polycystic ovary syndrome research underfunded?",
abstract = "Context: Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic abnormality with a worldwide prevalence of 4{\%} to 21{\%}, depending on diagnostic criteria. The National Institutes of Health (NIH) is the largest single funding agency in the world; it invests nearly $30.0 billion annually in biomedical research. Evidence Acquisition: Using the NIH Research Portfolio Online Reporting tool, we searched for all grants awarded by the NIH for PCOS and three other disorders with similar degrees of morbidity and similar or lower mortality and prevalence [rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE)]. Evidence Synthesis: We compared funding by the NIH for PCOS, RA, TB, and SLE research for the years 2006 to 2015, inclusive. Conclusion: PCOS, compared with RA, TB, and SLE, was relatively less funded (total mean 10-year funding was $215.12 million vs $454.39 million, $773.77 million, and $609.52 million, respectively). Funding for PCOS was largely provided by one NIH Institute/Center (ICs) vs at least two ICs for SLE and RA; more individual Research Project Grants were awarded for RA, SLE, and TB than for PCOS, whereas PCOS funding was more likely to be through General Clinical Research Centers Program or Specialized Centers Program awards. Our data suggest that PCOS research may be underfunded considering its prevalence, economic burden, metabolic morbidity, and negative impact on quality of life. Greater education of NIH leaders, including those at the National Heart, Lung, and Blood Institute and National Institutes of Diabetes and Digestive and Kidney Diseases; other federal and state agency leads; elected leaders; and the general public by professional societies, the scientific community, and patient advocates regarding this disorder is needed.",
author = "Soumia Brakta and Daria Lizneva and Kateryna Mykhalchenko and Adonis Imam and Walidah Walker and Diamond, {Michael Peter} and Ricardo Azziz",
year = "2017",
month = "1",
day = "1",
doi = "10.1210/jc.2017-01415",
language = "English (US)",
volume = "102",
pages = "4421--4427",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Perspectives on polycystic ovary syndrome

T2 - Is polycystic ovary syndrome research underfunded?

AU - Brakta, Soumia

AU - Lizneva, Daria

AU - Mykhalchenko, Kateryna

AU - Imam, Adonis

AU - Walker, Walidah

AU - Diamond, Michael Peter

AU - Azziz, Ricardo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Context: Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic abnormality with a worldwide prevalence of 4% to 21%, depending on diagnostic criteria. The National Institutes of Health (NIH) is the largest single funding agency in the world; it invests nearly $30.0 billion annually in biomedical research. Evidence Acquisition: Using the NIH Research Portfolio Online Reporting tool, we searched for all grants awarded by the NIH for PCOS and three other disorders with similar degrees of morbidity and similar or lower mortality and prevalence [rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE)]. Evidence Synthesis: We compared funding by the NIH for PCOS, RA, TB, and SLE research for the years 2006 to 2015, inclusive. Conclusion: PCOS, compared with RA, TB, and SLE, was relatively less funded (total mean 10-year funding was $215.12 million vs $454.39 million, $773.77 million, and $609.52 million, respectively). Funding for PCOS was largely provided by one NIH Institute/Center (ICs) vs at least two ICs for SLE and RA; more individual Research Project Grants were awarded for RA, SLE, and TB than for PCOS, whereas PCOS funding was more likely to be through General Clinical Research Centers Program or Specialized Centers Program awards. Our data suggest that PCOS research may be underfunded considering its prevalence, economic burden, metabolic morbidity, and negative impact on quality of life. Greater education of NIH leaders, including those at the National Heart, Lung, and Blood Institute and National Institutes of Diabetes and Digestive and Kidney Diseases; other federal and state agency leads; elected leaders; and the general public by professional societies, the scientific community, and patient advocates regarding this disorder is needed.

AB - Context: Polycystic ovary syndrome (PCOS) is a common endocrine-metabolic abnormality with a worldwide prevalence of 4% to 21%, depending on diagnostic criteria. The National Institutes of Health (NIH) is the largest single funding agency in the world; it invests nearly $30.0 billion annually in biomedical research. Evidence Acquisition: Using the NIH Research Portfolio Online Reporting tool, we searched for all grants awarded by the NIH for PCOS and three other disorders with similar degrees of morbidity and similar or lower mortality and prevalence [rheumatoid arthritis (RA), tuberculosis (TB), and systemic lupus erythematosus (SLE)]. Evidence Synthesis: We compared funding by the NIH for PCOS, RA, TB, and SLE research for the years 2006 to 2015, inclusive. Conclusion: PCOS, compared with RA, TB, and SLE, was relatively less funded (total mean 10-year funding was $215.12 million vs $454.39 million, $773.77 million, and $609.52 million, respectively). Funding for PCOS was largely provided by one NIH Institute/Center (ICs) vs at least two ICs for SLE and RA; more individual Research Project Grants were awarded for RA, SLE, and TB than for PCOS, whereas PCOS funding was more likely to be through General Clinical Research Centers Program or Specialized Centers Program awards. Our data suggest that PCOS research may be underfunded considering its prevalence, economic burden, metabolic morbidity, and negative impact on quality of life. Greater education of NIH leaders, including those at the National Heart, Lung, and Blood Institute and National Institutes of Diabetes and Digestive and Kidney Diseases; other federal and state agency leads; elected leaders; and the general public by professional societies, the scientific community, and patient advocates regarding this disorder is needed.

UR - http://www.scopus.com/inward/record.url?scp=85038228688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038228688&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-01415

DO - 10.1210/jc.2017-01415

M3 - Review article

C2 - 29092064

AN - SCOPUS:85038228688

VL - 102

SP - 4421

EP - 4427

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -